Sign inJoin waitlistJoin the waitlist

Sarah Lynam

Co-Leader, Gynecology Disease Team, UH Seidman Cancer Center · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · · · ·

History

Gynecology Disease Team · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
UH Cleveland Medical Center Hospital · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Case Western Reserve University/University Hospitals Cleveland Medical Center
Present

Roswell Park Comprehensive Cancer Center
2017–2021
Obstetrics and Gynecology
University of Maryland Medical Center
2013–2017
University of Maryland School of Medicine
2009–2013
Towson University
2004–2008

Research

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized…
JAMA Oncology · 2021 · 189 citations
Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery
JAMA Network Open · 2018 · 101 citations
Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions
Review · Clinical Obstetrics & Gynecology · 2020 · First of 3 authors · 34 citations

Emese Zsiros
3 papers
Peter Frederick
3 papers
Graham Chapman
2 papers · 2 as a fellow
JS
James Szender
2 papers · 2 as a fellow
JM
Jaron Mark
2 papers
Kristen Starbuck
2 papers · 1 as a fellow
SL
Shashikant Lele
2 papers
Stacey Akers
2 papers
Stacy Smrz
2 papers · 1 as a fellow
Abdul Naqash
1 paper
Afshin Dowlati
1 paper
Allie Reid
1 paper · 1 as a fellow

Clinical trials

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Principal investigator · Recruiting · Phase 2
Sarah K. Lynam MD
2022–2027
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Site PI · Recruiting · Phase 3
GOG Foundation
2024–2034